The U.S. Patent and Trademark Office has kicked a major patent dispute between Affymetrix Inc. and Incyte Pharmaceuticals Inc. back to the Northern District Court of California.
The PTO’s Board of Patent Appeals and Interferences ruled that Palo Alto-based Inctye had failed to provide sufficient evidence that Affymetrix’s claims for its GeneChip patents were not supported by a written description.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
